CARSgen的临床试验信息如下,有需要的朋友也可以看看:
Anti-GPC3 CAR T for Treating Patients With Advanced HCC
This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2015 by RenJi Hospital
Sponsor:
RenJi Hospital
Information provided by (Responsible Party):
RenJi Hospital
ClinicalTrials.gov Identifier:
NCT02395250
First received: March 17, 2015
Last updated: NA
Last verified: March 2015
History: No changes posted
Full Text View
Tabular View
No Study Results Posted
Disclaimer
How to Read a Study Record
Purpose
The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize glypican-3 (GPC3) is safe and effective for patients with relapsed or refractory hepatocellular carcinoma (HCC).
Condition Intervention Phase
Hepatocellular Carcinoma
Biological: anti-GPC3 CAR T
Phase 1
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Autologous T Cells Redirected to GPC3 for Treating Patients With Advanced HCC